GlassScriptPhysician profile
Scott P Prawer
NPI 1013103837
$791.43
in general payments reported to CMS, 2019-2025
22 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.34 · 2020: $52.60 · 2022: $49.89 · 2023: $224 · 2024: $233 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $110.40 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $87.34 | 2019-2023 | Dupixent |
| Leo Pharma INC. | $58.07 | 2023-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $56.31 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $50.38 | 2019-2023 | Winlevi |
| Amgen INC. | $45.65 | 2024-2025 | Otezla |
| Dermavant Sciences, INC. | $39.70 | 2023-2024 | Vtama |
| Biofrontera INC. | $37.79 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mylan Institutional INC. | $37.57 | 2023 | Hulio |
| Novartis Pharmaceuticals Corporation | $31.87 | 2023-2025 | |
| Ucb, INC. | $31.80 | 2022-2023 | Bimzelx |
| Galderma Laboratories, L.P. | $30.73 | 2023-2025 | Aklief, Nemluvio |
| Janssen Biotech, INC. | $28.91 | 2024 | Tremfya |
| Lilly USA, LLC | $27.00 | 2019-2022 | |
| Krystal Biotech INC | $20.57 | 2024 | Vyjuvek |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2024 | |
| Arcutis Biotherapeutics, INC. | $15.58 | 2024 | Zoryve |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $14.05 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $13.31 | 2024 | |
| Celgene Corporation | $12.90 | 2019 | |
| Dermira, INC. | $12.83 | 2020 | |
| Pierre Fabre Pharmaceuticals, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Prawer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.